CHINESE WORMWOOD HAS PROVEN ACTIVITY AGAINST CANCER CELLS

A large amount of scientific research has shown that artemesinin, a potent compound in the Chinese wormwood plant (Artemisia annua), can kill 98% of breast cancer cells in less than 16 hours.

The herb used alone caused a 28% reduction in breast cancer cells, but when paired with iron, sweet wormwood was able to eradicate cancer almost entirely with no negative effect on healthy, normal cells. Although the mechanism of its anticancer signalling is not well understood, Artemisinin inhibited proliferation and induced a strong G1 cell cycle arrest of cultured MCF7 cells, an estrogen-responsive human breast cancer cell line that represents an early-stage cancer phenotype, effectively inhibited the in-vivo growth of MCF7 cell-derived tumors from xenografts in athymic nude mice and induced a growth arrest of tumorigenic human breast cancer cell lines.

You can read the abstract of the research here: http://www.ncbi.nlm.nih.gov/pubmed/22185819

Yours in Great Health,

Specializing in Anxiety & Depression | Women’s Health | Chronic Fatigue | Natural Hormone Therapy | Thyroid Disorders | Digestive Health | Autoimmune Disease | Genetic Polymorphisms & Nutrigenomics | Nutritional Medicine | Counselling | Optimal Wellness & Disease Prevention with a Clinical Focus on Identifying & Resolving the Underlying Causes of Symptoms and Disease. 

Helping you achieve optimal wellness, hormonal balance and disease prevention with personalised, professional naturopathic health care, specialized clinical pathology testing and high-quality herbal medicines and supplements 

Want to keep up to date on the latest in health and wellbeing? Join Sar on Facebook by clicking this link: http://www.facebook.com/EarthMedicineHealth and “Like” our page to receive updates   

Reference: Anticancer Drugs. 2012 Apr;23(4):370-9. doi: 10.1097/CAD.0b013e32834f6ea8. Tin AS, Sundar SN, Tran KQ, Park AH, Poindexter KM, Firestone GL. Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes.